We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

HIV and Fat Accumulation (MATH)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01088295
First Posted: March 17, 2010
Last Update Posted: June 30, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
California HIV/AIDS Research Program
Information provided by (Responsible Party):
Jordan E. Lake M.D., University of California, Los Angeles
Results First Submitted: January 16, 2013  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: HIV Infection
Intervention: Drug: Telmisartan

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Subjects were recruited between May and October 2010 at the UCLA CARE Center.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Telmisartan Telmisartan 40mg po daily for 24 weeks

Participant Flow:   Overall Study
    Telmisartan
STARTED   36 
COMPLETED   35 
NOT COMPLETED   1 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Telmisartan Telmisartan 40mg po daily for 24 weeks

Baseline Measures
   Telmisartan 
Overall Participants Analyzed 
[Units: Participants]
 36 
Age 
[Units: Participants]
 
<=18 years   0 
Between 18 and 65 years   36 
>=65 years   0 
Age 
[Units: Years]
Mean (Standard Deviation)
 49  (7.4) 
Gender 
[Units: Participants]
 
Female   16 
Male   20 
Region of Enrollment 
[Units: Participants]
 
United States   36 


  Outcome Measures

1.  Primary:   Median Change in Visceral Adipose Tissue (VAT) Volume   [ Time Frame: Baseline and 24 weeks ]

2.  Secondary:   Safety and Tolerability of Telmisartan   [ Time Frame: 24 weeks ]
Results not yet reported.   Anticipated Reporting Date:   No text entered.  


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats


  More Information